Table 1 Clinical demographics in this study
From: WNT16 elevation induced cell senescence of osteoblasts in ankylosing spondylitis
| Â | Bone tissue donor | Serum donor | ||
|---|---|---|---|---|
disease controls (n=7) | AS patients (n=7) | healthy controls (n=30) | AS patients (n=36) | |
Age, year | 54.1 (59–46) | 43.4 (37–47) | 31.0 (28.0–36.3) | 54.4 (44.3–60.9) |
Male sex | 7, 100% | 7, 100% | 30, 100% | 36, 100% |
HLA-B27 positivity | 0, 0% | 7, 100% | 30, 0% | 28, 100% (n=28) |
Symptom duration, year | N/A | 14.5 (7.0–22.0) | N/A | 19.6 (11.4–25.2) |
mSASSS | N/A | N/A | N/A | 33.4 (9.0–55.8) |
CRP | N/A | 0.4 (0.4–2.4) | N/A | 0.4 (0.4–1.0) (n=35) |
Spinal BMD | N/A | N/A | N/A | 1.07 (0.9–1.3) |
Spinal T-score | N/A | N/A | N/A | 0.35 (−0.7–2.4) |
Use of TNF inhibitors | 0, 0% | 4, 57.1% | 0, 0% | 24, 66.7% |